for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NicOx SA

NCOX.PA

Latest Trade

4.70EUR

Change

-0.02(-0.32%)

Volume

20,348

Today's Range

4.59

 - 

4.73

52 Week Range

4.30

 - 

7.15

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
4.72
Open
4.59
Volume
20,348
3M AVG Volume
1.32
Today's High
4.73
Today's Low
4.59
52 Week High
7.15
52 Week Low
4.30
Shares Out (MIL)
29.91
Market Cap (MIL)
141.05
Forward P/E
-7.99
Dividend (Yield %)
--

Next Event

Nicox SA Annual Shareholders Meeting

Latest Developments

More

Nicox Q3 Net Revenue Up At 0.5 Million Euros

Nicox Amends Bond Agreement With Kreos, Draws Down Further 4 Million Euros

Nicox H1 Net Loss Lowers To EUR 0.8 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NicOx SA

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

Industry

Biotechnology & Drugs

Contact Info

Drakkar 2 - Batiment D

2405 route des Dolines

CS 10313 Sophia Antipolis

+33.4.97245300

http://www.nicox.com

Executive Leadership

Michele Garufi

Chairman of the Board and Chief Executive Officer, Member of the Management Committee

Sandrine Gestin

Finance Director, Member of the Management Committee

Michael Bergamini

Executive Vice President, Chief Scientific Officer, Member of the Management Committee

Gavin Spencer

Executive Vice President & Chief Business Officer, Member of the Management Committee

Tomas Navratil

Vice President, Head of Development, Member of the Management Committee

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-0.280

2017

-0.310

2018

-0.630

2019(E)

-0.590
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.14
Price To Book (MRQ)
1.23
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.87
LT Debt To Equity (MRQ)
6.05
Return on Investment (TTM)
-8.40
Return on Equity (TTM)
-7.98

Latest News

Latest News

Nicox teams up with Chinese firm to develop and sell glaucoma drug

French ophthalmology company Nicox <NCOX.PA> and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive licence agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.

Healthcare group Nicox postpones NASDAQ listing due to market volatility

French healthcare and ophthalmology company Nicox said it had decided to postpone plans to list shares on the U.S. NASDAQ stock market, in the latest example of a company dropping stock market flotation plans due to market volatility.

BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros

* AS OF MARCH 31, 2018, THE GROUP HAD CASH AND CASH EQUIVALENTS OF €36.3 MILLION AS COMPARED WITH €41.4 MILLION AT DECEMBER 31, 2017

BRIEF-Nicox Opening Of U.S. Development Office In Research Triangle Park, North Carolina

* REG-NICOX: OPENING OF U.S. DEVELOPMENT OFFICE IN RESEARCH TRIANGLE PARK, NORTH CAROLINA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Nicox Announces Increase In Royalties From Bausch + Lomb For Vyzulta

* REG-NICOX ANNOUNCES IMPROVED FINANCIAL TERMS FROM BAUSCH + LOMB FOR VYZULTA

BRIEF-Nicox Provides 2018 Outlook And 2017 Estimated Financial Results

* ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, U.S. LAUNCH PLANNED BY PARTNER EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON

BRIEF-Nicox Updates on Drug Development And Outlines 2018 Activities

* RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT

BRIEF-Bausch + Lomb and Nicox announces FDA approval of Vyzulta

* Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

BRIEF-‍Nicox enters research collaboration with Re-Vana Therapeutics

* Nicox enters research collaboration with Re-Vana Therapeutics on its next generation of stand-alone no-donors in a novel sustained release ophthalmic formulation

BRIEF-Nicox and pSivida enter strategic collaboration agreement

* REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA

BRIEF-Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​

* Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma

BRIEF-Nicox announces licensing agreement with Eyevance

* ANNOUNCES LICENSING AGREEMENT WITH EYEVANCE FOR COMMERCIALIZATION OF ZERVIATETM IN UNITED STATES

BRIEF-Nicox H1 operating loss narrows to 11.6 million euros

* ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% NEW DRUG APPLICATION (NDA) APPROVED

BRIEF-NicOx raises $31 million in private placement of shares

* ANNOUNCED ON THURSDAY A PRIVATE PLACEMENT OF SHARES TO RAISE EUR 26.25 MILLION (USD 30.97 MILLION)

BRIEF-Nicox lists 3.5 million new shares on Euronext Paris

* NICOX SA TO LIST 3.5 MILLION NEW SHARES ON EURONEXT PARIS AS OF AUGUST 17; REFERENCE PRICE: EUR 7.5 Further company coverage: (Gdynia Newsroom)

BRIEF-Nicox announces 26.25 million euros financing

* NICOX SA - RESERVED CAPITAL INCREASE OF ORDINARY SHARES OF COMPANY TO A SPECIFIC CATEGORY OF INVESTORS

BRIEF-Nicox launches capital increase of 597,897 euros following FDA's approval of Zerviate

* ANNOUNCED ON THURSDAY ISSUING AND ADMISSION TO TRADING ON THE EURONEXT REGULATED MARKET IN PARIS OF 597,897 NEW SHARES AWARDED TO EXISTING ACIEX SHAREHOLDERS FOLLOWING THE US FDA'S APPROVAL OF ZERVIATE

BRIEF-Nicox receives FDA approval of Zerviate1 0.24 pct

* Nicox receives FDA approval of ZERVIATE1 (cetirizine ophthalmic solution) 0.24% Source text for Eikon: Further company coverage:

BRIEF-Nicox receives FDA approval of ZERVIATE1 (cetirizine ophthalmic solution) 0.24%

* REG-NICOX RECEIVES FDA APPROVAL OF ZERVIATE1 (CETIRIZINE OPHTHALMIC SOLUTION) 0.24%

BRIEF-Nicox announces presentation of scientific data on NCX 667

* NICOX ANNOUNCES THE PRESENTATION OF SCIENTIFIC DATA ON NCX 667 AT ARVO 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up